Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS

X
Trial Profile

PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Futibatinib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Anaplastic astrocytoma; Appendiceal cancer; Biliary cancer; Brain cancer; Cervical cancer; Cholangiocarcinoma; CNS cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Glioblastoma; Glioma; Head and neck cancer; Mesothelioma; Neuroblastoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Oligodendroglioma; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Sarcoma; Skin cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms FOENIX-101; FOENIX-CCA2
  • Sponsors Taiho Oncology
  • Most Recent Events

    • 20 Feb 2024 Status changed from active, no longer recruiting to completed.
    • 23 Sep 2023 This trial has been completed in Spain and Germany , according to European Clinical Trials Database record.
    • 04 Jul 2023 According to a Taiho Oncology media release, John Bridgewater is the Investigator and Senior Author of the NEJM publication.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top